Xilio Ther­a­peu­tics goes pub­lic as bio­phar­ma IPOs rum­ble for­ward in Q4

It’s been a busy fall on Wall Street — and this week, we’ve got an­oth­er biotech go­ing pub­lic af­ter Ven­tyx yes­ter­day.

Mass­a­chu­setts sol­id-tu­mor biotech Xilio Ther­a­peu­tics made its pub­lic de­but to­day, join­ing 149 oth­er biotechs that have gone pub­lic so far this year.

Back on Oc­to­ber 1st, Xilio filed its S-1 with the SEC to make its IPO de­but for $100 mil­lion — the next step in fi­nanc­ing af­ter com­plet­ing a $95 mil­lion Se­ries C back in Feb­ru­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER